AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Phase 3
Recruiting
- Conditions
- HER2-positive Gastric CancerGastroesophageal Junction Adenocarcinoma
- Interventions
- First Posted Date
- 2025-01-09
- Last Posted Date
- 2025-04-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 840
- Registration Number
- NCT06764875
- Locations
- 🇻🇳
Research Site, Vinh, Vietnam
A Phase IIIB Study to Evaluate the Use of Capivasertib in Combination With Fulvestrant in Patients With Advanced Breast Cancer Who Have Relapsed/Progressed on ET and CDK4/6 Inhibitor Reflecting Real World Clinical Practice in Spain
Phase 3
Recruiting
- Conditions
- Locally Advanced or Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2025-01-08
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 100
- Registration Number
- NCT06764186
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
Clinical and Demographic Features of Patients With Moderate to Severe Active Systemic Lupus Erythematosus in Russia
Recruiting
- Conditions
- Systemic Lupus Erythematosus
- First Posted Date
- 2025-01-06
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 600
- Registration Number
- NCT06759519
- Locations
- 🇷🇺
Research Site, Yaroslavl, Russian Federation
Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of Ceralasertib
Phase 1
Not yet recruiting
- Conditions
- Neoplasm
- Interventions
- Drug: [14C] AZD6738
- First Posted Date
- 2025-01-01
- Last Posted Date
- 2025-01-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 8
- Registration Number
- NCT06754761
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-04-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 231
- Registration Number
- NCT06749457
- Locations
- 🇺🇸
Research Site, Beaumont, Texas, United States
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
Phase 3
Recruiting
- Conditions
- Eosinophilic Asthma
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-05-01
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 400
- Registration Number
- NCT06750289
- Locations
- 🇬🇧
Research Site, Portsmouth, United Kingdom
A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-05-15
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 36
- Registration Number
- NCT06750276
- Locations
- 🇬🇧
Research Site, London, United Kingdom
A Study to Evaluate the Use of Durvalumab in Combination With Platinum-based Chemotherapy Followed by Durvalumab With Olaparib as First-line Treatment in Advanced or Recurrent Endometrial Cancer in Spain
Phase 3
Recruiting
- Conditions
- Advanced or Recurrent Endometrial Cancer
- Interventions
- First Posted Date
- 2024-12-24
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 85
- Registration Number
- NCT06746116
- Locations
- 🇪🇸
Research Site, Zaragoza, Spain
A Comparative Effectiveness Study of Mortality Outcomes and Related Cardiopulmonary Events Among a Cohort of Chronic Obstructive Pulmonary Disease (COPD) Patients Who Initiate Breztri and Multiple Inhaler Triple Therapy (MITT) in the United States (US)
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 22369
- Registration Number
- NCT06744374
- Locations
- 🇺🇸
AstraZeneca, Wilmington, Delaware, United States
Prospective Observational Multicenter Study of Patients With AH and CKD Markers in Kazakhstan (PROGRESS-CKD)
Recruiting
- Conditions
- Rate of CKD Diagnosis in Patients With AH and CKD MarkersDemographic and Clinical Characteristics for Those PatientsRoutine Therapy Before and After the Diagnosis of CKD
- First Posted Date
- 2024-12-20
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1282
- Registration Number
- NCT06744335
- Locations
- 🇰🇿
Research Site, Temirlanovka Village, Kazakhstan
© Copyright 2025. All Rights Reserved by MedPath